No Detail Found!

Prevalence of covid-19 breakthrough after vaccination and adverse effects of vaccines

Author(s)
Fatima Ehsan Department of Endocrinilogy and Diabetes, Riphah International University, Islamabad, Pakistan
Fouzia Hanif Department of Medicine, Riphah International University, Islamabad, Pakistan
Qudsia Ishaq Department of Biochemistry, Federal Medical and Dental CollegeI, Islamabad, Pakistan
Maleha Asim Department of Medicine, Riphah International University, Islamabad, Pakistan
Maria Yousaf Department of Biochemistry, Bilal Hospital, Islamabad, Pakistan
Aqeel Mansoor Department of Physiology, Riphah International University, Islamabad, Pakistan
Abstract
Objective: To assess the prevalence of breakthrough Covid 19 after vaccination and adverse effects of vaccines. Methodology: This descriptive cross-sectional study was conducted at three mega vaccination centers in Islamabad from December 1, 2021, to May 1, 2022. The sample size consisted of 300 participants in the age range of 30-60 years. We included only those participants who were fully vaccinated. Among these, 150 were healthy individuals and 150 had comorbidities, were selected through convenience sampling. Data were analyzed using SPSS version 21. Results: A significant association between breakthrough COVID-19 and age and symptoms were found in fully vaccinated individuals with and without comorbidities. The type of vaccine had a significant association only in individuals without medical illness. No significant side effects of the vaccine or gender association were found in either group. We also found a significant association between breakthrough COVID-19 symptoms and the type of vaccine used. Conclusion: A significant association between vaccine type and breakthrough COVID was observed only in healthy individuals, probably because of their different mechanisms of action.
Publication Details
Page(s) 1-4
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 49, Issue: 2, Year: 2024

Request the full text from PASTIC

Keywords
Pakistan, Vaccines, covid 19., comorbidities
References
Zhou P,Yang X-L,Wang X-G,Hu B,Zhang L,Zhang W .2020 .A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798) : 270-3.
Yin Y,Wunderink RG .2018 .MERS, SARS and other coronaviruses as causes of pneumonia. Respirology, 23 : 130-137.
Hui DS,Madani I Azhar E,Ntoumi TA,Kock F,Dar R,O R .2020 .The continuing 2019-ncov epidemic threat of novel coronaviruses to Global Health - the latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 91 : 264-6.
Baden LR,El Sahly HM,Essink B,Kotloff K,Frey S,Novak R,SARS-CoV- R,Vaccine. N Engl J Med R .2021 .Efficacy and Safety of the mRNA-. , 384(5) : 403-416.
Vallianou NG,Tsilingiris D,Christodoulatos GS,Karampela I,Dalamaga M .2021 .Anti-viral treatment for SARSCoV-2 infection: A race against time amidst the ongoing pandemic. Metabol Open, 10 : 100096.
Barda N,Dagan N,Ben-Shlomo Y,Kepten E,Waxman J,Ohana R .2021 .. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, (12) : 1078-1090.
Choi A,Ibañez LI,Strohmeier S,Krammer F,GarcíaSastre A,Schotsaert M .2020 .Non-sterilizing, InfectionPermissive Vaccination with Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity from Cellular to Humoral Cross-Reactive Immune Responses. Front Immunol, 01166(11) : 1166.
Misu T,Kortepeter CM,Muñoz MA,Wu E,Dal Pan GJ .2018 .An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance. Drugs Real World Outcomes, 5(2) : 91-99.
Di Fusco M,Moran MM,Cane A,Curcio D,Khan F,Malhotra D .2021 .Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2. J Med Econ, 24(1) : 1248-1260.
Ul Munamm SA,Nadeem I,Mahdi N,Saqlain M,Rana ZK,Khatana UF,J R Coll Physicians Edin UF .2022 .Comparative analysis of mRNA and inactivated COVID-19 vaccines: A study from Faisalabad district of Pakistan. , 52(3) : 240-246.
Ben Fredj S,Ghammem R,Zammit N,Maatouk A,Hadded N,Laadhari H,Ben Fredj Eur J Public Health Sihem .2022 .Characteristics of COVID19 cases with breakthrough infection in the governorate of Sousse. , 32(Suppl 3) : 451-2.
Abbas S,Abbas B,Amir S,Wajahat M .2021 .Evaluation of adverse effects with COVID-19 vaccination in Pakistan. Pak J Med Sci, 37(7) : 1959-1964.
Cohen KW,Linderman SL,Moodie Z,Czartoski J,Lai L,Mantus G,Norwood C .2021 .Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med, 100354(7) : 100354.
Brunelli SM,Sibbel S,Karpinski S,Marlowe G,Walker AG,Giullian J .2022 .Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2. S Vaccine for the Prevention of COVID-19 among Dialysis Patients. J Am Soc Nephrol, 33(4) : 688-697.
Galmiche S,Luong Nguyen LB,Tartour E,de Lamballerie X,Wittkop L,Loubet P .2022 .Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect, 28(2) : 163-177.
Mahase E .2022 .Vaccinated people are less likely to get long covid, review finds. BMJ, 16 : 376.
0

Citations

0

Downloads

53

Views